Clinical Trial for the Safety and Efficacy of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma is a PHASE2 clinical asset sponsored by Zhejiang University in Multiple Myeloma, New Diagnosis Tumor. SEO and diligence focus: BCMA CAR-T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.